Degos disease

Lore & Background

Degos disease was first described in 1941 by Köhlmeier, and recognized as a new clinical entity by Robert Degos in 1942. The condition is characterized by the development of circular papules with a porcelain-white center and red border, typically appearing on the trunk and upper extremities. Papules range from 0.5 to 1 cm in width and are not found on the palms, soles, scalp, or face.

The disease has both a benign and a malignant variant. In the benign form, only the papules are present and may persist for years or throughout life. The malignant form involves internal organs, most commonly the gastrointestinal tract, leading to abdominal pain, diarrhea, and bowel perforation, as well as the central nervous system, heart, lungs, and kidneys. Symptoms can include headaches, seizures, stroke, double vision, shortness of breath, and chest pain. A person with the benign form may suddenly develop the malignant form.

Reader's Guide

Degos disease is significant as an extremely rare and poorly understood condition with fewer than 200 reported cases in medical literature. Its underlying mechanism remains unknown, though hypotheses include inflammation of blood vessels, coagulopathy, or abnormal swelling of vascular endothelium. Diagnosis relies on clinical evaluation of characteristic papules and histological findings showing wedge-shaped connective tissue necrosis. No effective treatment has been established; fibrinolytic and immunosuppressive therapies have been mostly unsuccessful. Recent research has shown improvement with eculizumab and treprostinil, though eculizumab's effect is of limited duration and expensive, requiring infusion every 14 days. All known long-term survivors of systemic Degos disease are being treated with a combination of eculizumab and treprostinil. The disease's rarity and diagnostic challenges mean many individuals may go undiagnosed.

Did You Know?

• The characteristic papules have a porcelain-white center and red border, and are not found on the palms, soles, scalp, or face.
• Fewer than 50 living patients are known worldwide, and fewer than 200 have been reported in medical literature.

The Two Faces of the Disease

The condition presents in two fundamentally different trajectories, and distinguishing between them is critical for patient management. In its milder expression, the disease manifests solely through the skin: small, circular bumps with a porcelain-white core ringed by a red border, typically measuring half to one centimeter across. These papules appear on the torso and upper arms but conspicuously spare the face, palms, soles, and scalp. Over time, the white centers atrophy and sink inward, leaving only the raised red rim. In this benign form, internal organs remain untouched, and the lesions can persist for years or even a lifetime without progressing. The malignant variant, however, introduces a far more dangerous dimension. Here, the same vascular blockages that create the skin lesions extend into the gastrointestinal tract, central nervous system, heart, lungs, and kidneys. Patients may experience abdominal pain, bowel perforation, seizures, stroke, cranial nerve paralysis, shortness of breath, and vision loss. Crucially, a person living with the benign form for years can suddenly shift into the malignant course, making vigilant follow-up essential.

The Unraveling Mystery

Despite roughly seven decades of medical observation, no one has definitively identified what triggers the vascular occlusions at the heart of this condition. The papules and organ damage all stem from blockages in small and medium-sized arteries and veins, yet the root cause of those blockages remains elusive. Several competing hypotheses have emerged over the years. One points to vascular inflammation as a possible initiator. Another frames the disease as a coagulopathy, where abnormal clot formation reduces blood flow, damages the endothelial lining, and ultimately produces the characteristic skin lesions. A third theory proposes that abnormal swelling and proliferation of the vascular endothelium sets off thrombosis in the intestines and brain, cascading into the full symptom picture. On the genetic front, the picture is equally uncertain. Some cases have appeared among first-degree relatives, leading researchers to speculate about an autosomal dominant inheritance pattern. However, this has never been confirmed, and in most familial clusters the milder, skin-only variant has been observed. Because the pathomechanism is unresolved, no prevention strategies exist, and the condition remains a mystery without a solution.

Identifying a Ghost

Diagnosing a condition with fewer than fifty known living patients worldwide and fewer than two hundred documented cases in the medical literature is an extraordinary challenge. The rarity itself becomes a barrier: many individuals likely go undiagnosed simply because clinicians have never encountered the condition before. When it is recognized, the process often begins with a dermatologist identifying the telltale papules—those small, round lesions with their distinctive white centers and red borders. A skin biopsy then provides histological confirmation, typically revealing a wedge-shaped area of connective tissue necrosis in the deeper dermis, a pattern that mirrors the occlusion of small feeding arteries. The diagnostic workup must also determine whether the disease is confined to the skin or has spread systemically. Depending on which organs are suspected, physicians may order brain imaging, colonoscopy, chest radiography, or abdominal ultrasound. The stakes of getting this assessment right are high, because a patient who has carried benign papules for years can abruptly develop the malignant, organ-involving form. Regular follow-up evaluations are therefore not optional but a matter of survival.

The Long Search for a Cure

No definitive cure exists for this condition, and the absence of one is a direct consequence of the unresolved pathophysiology. Because clinicians do not yet know precisely what initiates the vascular blockages, treatment has historically been limited to managing symptoms as they arise. Early therapeutic attempts have been largely disappointing. Fibrinolytic agents designed to dissolve clots and immunosuppressive regimens aimed at dampening inflammatory responses were both tested and found to be mostly unsuccessful. For years, this left patients with little more than supportive care. A more recent and encouraging development involves two drugs: eculizumab, a complement-inhibiting antibody, and treprostinil, a vasodilator. After first addressing comorbid conditions, physicians have observed symptomatic improvement in patients receiving these agents. Notably, dermatopathologist Cynthia Magro identified the response to eculizumab, which in some cases has been immediate and dramatic. However, the durability of that response remains limited, and the therapeutic picture is still evolving. With so few patients available for study, every case carries weight, and the search for a reliable, long-term treatment continues.

Gallery